- |||||||||| Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
Pain in the right leg. Analysis of a case. () - Oct 1, 2021 - Abstract #EUSEM2021EUSEM_4421; Retroperitoneal hematoma is a rare but potentially lethal entity that can present various clinical manifestations, which can be very non-specific with confusion in diagnosis and therefore delaying treatment. Having normal hemoglobin at onset does not always rule out active bleeding.
- |||||||||| Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
Pain in the right leg. Analysis of a case. () - Oct 1, 2021 - Abstract #EUSEM2021EUSEM_4420; Retroperitoneal hematoma is a rare but potentially lethal entity that can present various clinical manifestations, which can be very non-specific with confusion in diagnosis and therefore delaying treatment. Having normal hemoglobin at onset does not always rule out active bleeding.
- |||||||||| Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
Pain in the right leg. Analysis of a case. () - Oct 1, 2021 - Abstract #EUSEM2021EUSEM_4419; Retroperitoneal hematoma is a rare but potentially lethal entity that can present various clinical manifestations, which can be very non-specific with confusion in diagnosis and therefore delaying treatment. Having normal hemoglobin at onset does not always rule out active bleeding.
- |||||||||| Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
Pain in the right leg. Analysis of a case. () - Oct 1, 2021 - Abstract #EUSEM2021EUSEM_4418; Retroperitoneal hematoma is a rare but potentially lethal entity that can present various clinical manifestations, which can be very non-specific with confusion in diagnosis and therefore delaying treatment. Having normal hemoglobin at onset does not always rule out active bleeding.
- |||||||||| Atenativ (human antithrombin III) / Octapharma
Trial completion date, Trial primary completion date, Surgery: ATN-106: Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery (clinicaltrials.gov) - Sep 20, 2021 P3, N=34, Not yet recruiting, Overall 96% and 73% patients completed the first and extension period, with 3 (3%) and 9 (10%) subjects discontinuing due to adverse events (1 of 3 and 6 of 9 due to IVIg related events), respectively. Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
- |||||||||| Fibryga (fibrinogen concentrate (human)) / Octapharma
Clinical, Clinical protocol, Journal, Head-to-Head: Protocol for a multicentre, randomised, parallel-control, superiority trial comparing administration of clotting factor concentrates with a standard massive haemorrhage protocol in severely bleeding trauma patients: the FiiRST 2 trial (a 2020 EAST multicentre trial). (Pubmed Central) - Sep 17, 2021 P4 Fibrinogen concentrate (FC) and prothrombin complex concentrate (PCC) are two purified concentrates of clotting factors that have been used to treat ATC...If superiority is established, results will have a major impact on clinical practice by reducing exposure to non-virally inactivated blood products, shortening the time for administration of clotting factors, correct coagulopathy more efficaciously and reduce the reliance on AB plasma. NCT04534751, pre results.
- |||||||||| Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
Pain in the right leg. Analysis of a case. () - Sep 7, 2021 - Abstract #EUSEM2021EUSEM_811; Retroperitoneal hematoma is a rare but potentially lethal entity that can present various clinical manifestations, which can be very non-specific with confusion in diagnosis and therefore delaying treatment. Having normal hemoglobin at onset does not always rule out active bleeding.
- |||||||||| Octaplex (human prothrombin complex concentrate) / Octapharma, Pfizer
Trial completion date, Trial primary completion date, Surgery: Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex (clinicaltrials.gov) - Jul 15, 2021 P3, N=370, Recruiting, Recruiting --> Active, not recruiting | Trial completion date: Jul 2021 --> Jan 2022 | Trial primary completion date: Jul 2021 --> Jan 2022 Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
- |||||||||| Wilate (human factor VIII/von Willebrand factor) / Octapharma
Clinical, Journal, Real-world evidence: Real-World Data on the Effectiveness and Safety of wilate for the Treatment of von Willebrand Disease. (Pubmed Central) - Jul 9, 2021 Effectiveness was assessed as "excellent" or "good" by patients and investigators for 100% of BEs treated on-demand, 98% (patient rating) and 99% (investigator rating) of breakthrough BEs, and 99% of surgical procedures (investigator rating). Conclusion wilate was safe, well tolerated, and effective for the prevention and treatment of bleeding in pediatric and adult VWD patients in a real-world setting.
- |||||||||| Nuwiq (simoctocog alfa) / Octapharma
[VIRTUAL] New Insights into Prophylaxis with Simoctocog Alfa (Room 5) - Jul 3, 2021 - Abstract #ISTH2021ISTH_2903; Conclusion wilate was safe, well tolerated, and effective for the prevention and treatment of bleeding in pediatric and adult VWD patients in a real-world setting. This session is supported by Octapharma AG
- |||||||||| Octagam (intravenous normal human immunoglobulin) / Octapharma
Trial completion: Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19 (clinicaltrials.gov) - Jun 25, 2021 P4, N=34, Completed, Additionally, we suggest that the multiplex assay can be adopted by both companies and regulatory agencies to prevent commercial fraud in the marketing of processed fishery products in Brazil and other countries where these products are commercialized. Active, not recruiting --> Completed
- |||||||||| Wilate (human factor VIII/von Willebrand factor) / Octapharma, Nuwiq (simoctocog alfa) / Octapharma, Octanate (human Factor VIII/von Willebrand Factor) / Octapharma
[VIRTUAL] PRactical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia A Patients Entering Routine Clinical Treatment with Nuwiq®, octanate® or wilate® – The Protect-NOW Study (Room 3) - Jun 9, 2021 - Abstract #ISTH2021ISTH_987; Results : As of March 2021, 37 patients have been enrolled in the study from 13 sites in Belarus, Canada, France, Germany, Italy, Lithuania, Spain and the United Kingdom, with additional sites to be initiated. Conclusions : Protect-NOW is collecting clinically relevant information on the outcomes of PUPs and MTPs treated with Octapharma‘s FVIII products in a real-world setting.
- |||||||||| Nuwiq (simoctocog alfa) / Octapharma
[VIRTUAL] Long-term Prophylaxis with Simoctocog Alfa in Children (Room 3) - Jun 9, 2021 - Abstract #ISTH2021ISTH_896; None of the 96 patients on long-term prophylaxis withdrew from the studies due to an adverse event and there were no thrombotic events. Conclusions : Simoctocog alfa is efficacious and well-tolerated for long-term prophylaxis in children with severe haemophilia A and is an attractive long-term therapeutic option for children.
|